Celgene Acquisition by Bristol-Myers Squibb: A Call to Arbs
On January 3, 2019, Bristol Myers Squibb Co (BMY US) and Celgene Corp (CELG US) announced a definitive agreement for BMY to acquire Celgene in a...
1.1k Views
BeiGene IPO Preview: Lucrative Lifesavers
BeiGene (BGNE US) is set to become the first overseas listed biotech firm to seek a secondary listing in Hong Kong, under the city’s newly revamped...
793 Views
Binex - Paving the Way for Next-Gen Biotech Breakthrough
We met with Mr. HJ Lee, CEO & President of Binex, followed by a quick site tour in Incheon, Korea, and learned that the company has recently...
480 Views
Ophthotech: What Is Next?
We listened to the conference call by Ophthotech Corp (OPHT US) management (link). The results of the phase 3 trial were shocking to many investors...
532 Views
We Are Buying This Large Cap Biotechnology Company After Trump's Election Win
We have a Buy rating with price target of $173 (DCF method)=44% upside. The stock also appears to have upside using relative valuation measures...
737 Views